CN102946861B - 浓缩蛋白制剂及其用途 - Google Patents

浓缩蛋白制剂及其用途 Download PDF

Info

Publication number
CN102946861B
CN102946861B CN201180019594.5A CN201180019594A CN102946861B CN 102946861 B CN102946861 B CN 102946861B CN 201180019594 A CN201180019594 A CN 201180019594A CN 102946861 B CN102946861 B CN 102946861B
Authority
CN
China
Prior art keywords
preparation
amount
salt
formulations
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180019594.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102946861A (zh
Inventor
T·T·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytodyn Inc
Original Assignee
Progenics Pharmaceuticals Inc
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc, Cytodyn Inc filed Critical Progenics Pharmaceuticals Inc
Priority to CN201510815109.5A priority Critical patent/CN105521491B/zh
Publication of CN102946861A publication Critical patent/CN102946861A/zh
Application granted granted Critical
Publication of CN102946861B publication Critical patent/CN102946861B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201180019594.5A 2010-03-01 2011-03-01 浓缩蛋白制剂及其用途 Active CN102946861B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510815109.5A CN105521491B (zh) 2010-03-01 2011-03-01 浓缩蛋白制剂及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33919110P 2010-03-01 2010-03-01
US61/339,191 2010-03-01
PCT/US2011/026647 WO2011109365A2 (en) 2010-03-01 2011-03-01 Concentrated protein formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510815109.5A Division CN105521491B (zh) 2010-03-01 2011-03-01 浓缩蛋白制剂及其用途

Publications (2)

Publication Number Publication Date
CN102946861A CN102946861A (zh) 2013-02-27
CN102946861B true CN102946861B (zh) 2016-01-20

Family

ID=44542798

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180019594.5A Active CN102946861B (zh) 2010-03-01 2011-03-01 浓缩蛋白制剂及其用途
CN201510815109.5A Active CN105521491B (zh) 2010-03-01 2011-03-01 浓缩蛋白制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510815109.5A Active CN105521491B (zh) 2010-03-01 2011-03-01 浓缩蛋白制剂及其用途

Country Status (15)

Country Link
US (2) US9956165B2 (https=)
EP (1) EP2542221A4 (https=)
JP (2) JP5937523B2 (https=)
KR (1) KR101853981B1 (https=)
CN (2) CN102946861B (https=)
AU (2) AU2011223805B2 (https=)
BR (1) BR112012022223B1 (https=)
CA (1) CA2794929C (https=)
IL (1) IL221748B (https=)
MX (1) MX347504B (https=)
NZ (1) NZ602685A (https=)
RU (1) RU2626512C2 (https=)
SG (1) SG184355A1 (https=)
WO (1) WO2011109365A2 (https=)
ZA (1) ZA201207331B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594334B2 (en) 2016-05-31 2026-04-07 Gmax Biopharm Llc. ETAR antibody, and pharmaceutical compositions and use thereof

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
WO2014039903A2 (en) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
EP3345923A1 (en) * 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
JP6767367B2 (ja) * 2014-08-20 2020-10-14 サイトダイン インコーポレイテッドＣｙｔｏｄｙｎ Ｉｎｃ． 代替処置としてのｈｉｖ抗体療法
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
KR20170065662A (ko) * 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
JP6781508B2 (ja) 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
SG11201705484WA (en) * 2015-02-09 2017-08-30 Ucb Biopharma Sprl Pharmaceutical formulation
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
TW201726111A (zh) * 2015-09-30 2017-08-01 持田製藥股份有限公司 含高濃度抗體之液體製劑
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
AU2017305856B2 (en) * 2016-08-05 2024-09-12 Csl Behring Gmbh Pharmaceutical formulations of C1 esterase inhibitor
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
JP2020530004A (ja) * 2017-08-03 2020-10-15 ジャズ ファーマシューティカルズ アイルランド リミテッド 核酸を高濃度で含む製剤
KR102208378B1 (ko) * 2017-08-17 2021-01-28 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US20190085086A1 (en) 2017-09-18 2019-03-21 Cytodyn Inc. Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
BR112021021099A2 (pt) * 2019-04-23 2021-12-14 Sanofi Sa Formulações de anticorpos estáveis, de baixa viscosidade, e usos das mesmas
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CA3172627A1 (en) * 2020-04-22 2021-10-28 Adi Mor Method of treatment using anti-ccl24 antibody
CN115996748A (zh) * 2020-05-29 2023-04-21 奇努克医疗公司 用APRIL结合抗体治疗IgA肾病的方法
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
CN116034985B (zh) * 2022-12-12 2025-09-16 武汉呵尔医疗科技发展有限公司 一种细胞保护液、hpv e6/e7质控片的制备方法及应用
WO2025089468A1 (ko) * 2023-10-27 2025-05-01 주식회사 엔솔바이오사이언스 펩타이드 함유 액상제제 및 그 제조방법

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
CN1607958A (zh) * 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
US20050175603A1 (en) * 2000-10-12 2005-08-11 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2006007412A2 (en) * 2004-06-16 2006-01-19 Nastech Pharmaceutical Company Inc. Peptide yy formulations having increased stability and resistance to microbial agents
CN1993139A (zh) * 2004-06-01 2007-07-04 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
US20070172479A1 (en) * 2005-12-21 2007-07-26 Wyeth Protein formulations with reduced viscosity and uses thereof
US20080124326A1 (en) * 2006-10-20 2008-05-29 Amgen Inc. Stable polypeptide formulations
EP1478394B1 (en) * 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
AU2003211990A1 (en) 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
DE60324664D1 (de) 2002-02-22 2008-12-24 Pdl Biopharma Inc Anti-ccr5 antikörper
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
KR101235507B1 (ko) 2003-02-28 2013-02-20 추가이 세이야쿠 가부시키가이샤 단백질을 함유하는 안정화 제제
US8333995B2 (en) * 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
UA97234C2 (ru) * 2005-11-01 2012-01-25 Уайєт Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175603A1 (en) * 2000-10-12 2005-08-11 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CN1607958A (zh) * 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
EP1478394B1 (en) * 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
CN1993139A (zh) * 2004-06-01 2007-07-04 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
WO2006007412A2 (en) * 2004-06-16 2006-01-19 Nastech Pharmaceutical Company Inc. Peptide yy formulations having increased stability and resistance to microbial agents
US20070172479A1 (en) * 2005-12-21 2007-07-26 Wyeth Protein formulations with reduced viscosity and uses thereof
US20080124326A1 (en) * 2006-10-20 2008-05-29 Amgen Inc. Stable polypeptide formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594334B2 (en) 2016-05-31 2026-04-07 Gmax Biopharm Llc. ETAR antibody, and pharmaceutical compositions and use thereof

Also Published As

Publication number Publication date
EP2542221A4 (en) 2013-10-23
KR20130010898A (ko) 2013-01-29
CA2794929A1 (en) 2011-09-09
SG184355A1 (en) 2012-11-29
HK1223835A1 (zh) 2017-08-11
MX347504B (es) 2017-04-28
RU2012141655A (ru) 2014-04-10
AU2011223805B2 (en) 2015-10-29
KR101853981B1 (ko) 2018-05-02
AU2016200495B2 (en) 2017-11-09
WO2011109365A3 (en) 2012-01-05
JP2016193911A (ja) 2016-11-17
BR112012022223A8 (pt) 2017-12-05
ZA201207331B (en) 2014-07-30
CN105521491A (zh) 2016-04-27
MX2012010114A (es) 2013-01-29
AU2011223805A1 (en) 2012-10-25
RU2626512C2 (ru) 2017-07-28
BR112012022223B1 (pt) 2022-08-09
US11571383B2 (en) 2023-02-07
CA2794929C (en) 2018-06-05
JP2013521296A (ja) 2013-06-10
US9956165B2 (en) 2018-05-01
JP5937523B2 (ja) 2016-06-22
BR112012022223A2 (pt) 2016-07-05
WO2011109365A2 (en) 2011-09-09
EP2542221A2 (en) 2013-01-09
JP6229007B2 (ja) 2017-11-08
US20180263898A1 (en) 2018-09-20
US20130216525A1 (en) 2013-08-22
AU2016200495A1 (en) 2016-02-18
CN102946861A (zh) 2013-02-27
IL221748B (en) 2019-09-26
NZ602685A (en) 2014-10-31
CN105521491B (zh) 2020-03-24

Similar Documents

Publication Publication Date Title
CN102946861B (zh) 浓缩蛋白制剂及其用途
ES2748526T3 (es) Formulaciones tamponadas estables que contienen polipéptidos
BRPI0620316A2 (pt) formulações de proteìnas com viscosidades reduzida e seus usos
TWI682788B (zh) 包含ｇｍ－ｃｓｆ中和化合物之液態調配物
US20240182554A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
CN101420972A (zh) 降低蛋白质聚集的方法
CA2866692A1 (en) Formulations which prevent formation of antibody aggregates
WO2023011502A1 (zh) 含有抗il-4r抗体的稳定制剂
KR20190071760A (ko) 약학적 제형 및 그의 제조 방법
US20250043027A1 (en) Formulation of highly concentrated pharmacologically active antibody
US20220332849A1 (en) Stabilized Formulations Containing Anti-MUC16 x Anti-CD3 Bispecific Antibodies
HK1223835B (zh) 浓缩蛋白制剂及其用途
TW202541845A (zh) 穩定醫藥製劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CYTODYN INC.

Free format text: FORMER OWNER: PROGENICS PHARMACEUTICALS, INC.

Effective date: 20141114

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20141114

Address after: oregon

Applicant after: CYTODYN, INC.

Address before: American New York

Applicant before: Progenics Pharm Inc.

C14 Grant of patent or utility model
GR01 Patent grant